nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.195	0.282	CbGbCtD
Fosamprenavir—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.132	0.19	CbGbCtD
Fosamprenavir—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.126	0.182	CbGbCtD
Fosamprenavir—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.112	0.162	CbGbCtD
Fosamprenavir—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0657	0.0949	CbGbCtD
Fosamprenavir—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.062	0.0897	CbGbCtD
Fosamprenavir—Osteonecrosis—Prednisolone—chronic obstructive pulmonary disease	0.00384	0.0124	CcSEcCtD
Fosamprenavir—Hyperlipidaemia—Formoterol—chronic obstructive pulmonary disease	0.00366	0.0119	CcSEcCtD
Fosamprenavir—Hyperlipidaemia—Arformoterol—chronic obstructive pulmonary disease	0.00366	0.0119	CcSEcCtD
Fosamprenavir—Gastrooesophageal reflux disease—Tiotropium—chronic obstructive pulmonary disease	0.00362	0.0117	CcSEcCtD
Fosamprenavir—Hypercholesterolaemia—Tiotropium—chronic obstructive pulmonary disease	0.00346	0.0112	CcSEcCtD
Fosamprenavir—Gastritis—Roflumilast—chronic obstructive pulmonary disease	0.00334	0.0108	CcSEcCtD
Fosamprenavir—Nephrolithiasis—Arformoterol—chronic obstructive pulmonary disease	0.00328	0.0106	CcSEcCtD
Fosamprenavir—Nephrolithiasis—Formoterol—chronic obstructive pulmonary disease	0.00328	0.0106	CcSEcCtD
Fosamprenavir—Osteonecrosis—Prednisone—chronic obstructive pulmonary disease	0.00279	0.00904	CcSEcCtD
Fosamprenavir—Gastrooesophageal reflux disease—Salbutamol—chronic obstructive pulmonary disease	0.00276	0.00894	CcSEcCtD
Fosamprenavir—Inflammation—Arformoterol—chronic obstructive pulmonary disease	0.00272	0.00882	CcSEcCtD
Fosamprenavir—Inflammation—Formoterol—chronic obstructive pulmonary disease	0.00272	0.00882	CcSEcCtD
Fosamprenavir—Opportunistic infection—Prednisone—chronic obstructive pulmonary disease	0.00258	0.00836	CcSEcCtD
Fosamprenavir—Inflammation—Salbutamol—chronic obstructive pulmonary disease	0.00257	0.00833	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Roflumilast—chronic obstructive pulmonary disease	0.00257	0.00832	CcSEcCtD
Fosamprenavir—Cardiac disorder—Roflumilast—chronic obstructive pulmonary disease	0.00242	0.00786	CcSEcCtD
Fosamprenavir—Immune system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00236	0.00765	CcSEcCtD
Fosamprenavir—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.00227	0.00737	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Salbutamol—chronic obstructive pulmonary disease	0.00208	0.00674	CcSEcCtD
Fosamprenavir—Angioedema—Roflumilast—chronic obstructive pulmonary disease	0.00208	0.00673	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Aminophylline—chronic obstructive pulmonary disease	0.00196	0.00636	CcSEcCtD
Fosamprenavir—Myalgia—Roflumilast—chronic obstructive pulmonary disease	0.00193	0.00627	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00192	0.00623	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Tiotropium—chronic obstructive pulmonary disease	0.00185	0.006	CcSEcCtD
Fosamprenavir—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00182	0.0059	CcSEcCtD
Fosamprenavir—Hypertriglyceridaemia—Prednisone—chronic obstructive pulmonary disease	0.00181	0.00586	CcSEcCtD
Fosamprenavir—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.0018	0.00584	CcSEcCtD
Fosamprenavir—Gastritis—Arformoterol—chronic obstructive pulmonary disease	0.00169	0.0055	CcSEcCtD
Fosamprenavir—Gastritis—Formoterol—chronic obstructive pulmonary disease	0.00169	0.0055	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.00169	0.00548	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.00169	0.00548	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.00165	0.00536	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.00162	0.00526	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.00161	0.00523	CcSEcCtD
Fosamprenavir—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.00161	0.00523	CcSEcCtD
Fosamprenavir—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.00161	0.00522	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.0016	0.00519	CcSEcCtD
Fosamprenavir—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.0016	0.00519	CcSEcCtD
Fosamprenavir—Blood triglycerides increased—Prednisone—chronic obstructive pulmonary disease	0.00158	0.00514	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.00152	0.00492	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Formoterol—chronic obstructive pulmonary disease	0.00149	0.00484	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.00149	0.00484	CcSEcCtD
Fosamprenavir—Immune system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00148	0.00481	CcSEcCtD
Fosamprenavir—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00147	0.00475	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Arformoterol—chronic obstructive pulmonary disease	0.00145	0.00472	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Formoterol—chronic obstructive pulmonary disease	0.00145	0.00472	CcSEcCtD
Fosamprenavir—Myocardial infarction—Formoterol—chronic obstructive pulmonary disease	0.00145	0.00469	CcSEcCtD
Fosamprenavir—Myocardial infarction—Arformoterol—chronic obstructive pulmonary disease	0.00145	0.00469	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.00143	0.00465	CcSEcCtD
Fosamprenavir—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.00143	0.00463	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00141	0.00457	CcSEcCtD
Fosamprenavir—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00137	0.00443	CcSEcCtD
Fosamprenavir—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00133	0.00431	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00131	0.00424	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00131	0.00424	CcSEcCtD
Fosamprenavir—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.00131	0.00423	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.0013	0.00422	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.0013	0.00422	CcSEcCtD
Fosamprenavir—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.0013	0.00421	CcSEcCtD
Fosamprenavir—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.0013	0.00421	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.00128	0.00416	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.00128	0.00414	CcSEcCtD
Fosamprenavir—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.00127	0.00413	CcSEcCtD
Fosamprenavir—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00127	0.00411	CcSEcCtD
Fosamprenavir—Haemoglobin—Salbutamol—chronic obstructive pulmonary disease	0.00126	0.00408	CcSEcCtD
Fosamprenavir—Haemorrhage—Salbutamol—chronic obstructive pulmonary disease	0.00125	0.00406	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.00124	0.00401	CcSEcCtD
Fosamprenavir—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.00123	0.00399	CcSEcCtD
Fosamprenavir—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.00123	0.00399	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.00123	0.00399	CcSEcCtD
Fosamprenavir—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.00123	0.00398	CcSEcCtD
Fosamprenavir—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00123	0.00398	CcSEcCtD
Fosamprenavir—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.00123	0.00398	CcSEcCtD
Fosamprenavir—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.00122	0.00395	CcSEcCtD
Fosamprenavir—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00121	0.00393	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00121	0.00392	CcSEcCtD
Fosamprenavir—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.0012	0.00391	CcSEcCtD
Fosamprenavir—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.0012	0.00388	CcSEcCtD
Fosamprenavir—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.0012	0.00388	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Prednisolone—chronic obstructive pulmonary disease	0.00119	0.00387	CcSEcCtD
Fosamprenavir—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00118	0.00382	CcSEcCtD
Fosamprenavir—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.00118	0.00382	CcSEcCtD
Fosamprenavir—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.00117	0.0038	CcSEcCtD
Fosamprenavir—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00117	0.00379	CcSEcCtD
Fosamprenavir—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00117	0.00379	CcSEcCtD
Fosamprenavir—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00116	0.00377	CcSEcCtD
Fosamprenavir—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.00116	0.00376	CcSEcCtD
Fosamprenavir—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.00115	0.00374	CcSEcCtD
Fosamprenavir—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.00115	0.00374	CcSEcCtD
Fosamprenavir—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00114	0.00371	CcSEcCtD
Fosamprenavir—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00113	0.00367	CcSEcCtD
Fosamprenavir—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00113	0.00366	CcSEcCtD
Fosamprenavir—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.0011	0.00357	CcSEcCtD
Fosamprenavir—Hypercholesterolaemia—Prednisone—chronic obstructive pulmonary disease	0.0011	0.00356	CcSEcCtD
Fosamprenavir—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.00109	0.00353	CcSEcCtD
Fosamprenavir—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.00108	0.00349	CcSEcCtD
Fosamprenavir—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00348	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.00106	0.00345	CcSEcCtD
Fosamprenavir—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00105	0.00342	CcSEcCtD
Fosamprenavir—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00105	0.00342	CcSEcCtD
Fosamprenavir—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00103	0.00335	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00101	0.00328	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00101	0.00327	CcSEcCtD
Fosamprenavir—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000995	0.00323	CcSEcCtD
Fosamprenavir—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000982	0.00318	CcSEcCtD
Fosamprenavir—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000982	0.00318	CcSEcCtD
Fosamprenavir—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000978	0.00317	CcSEcCtD
Fosamprenavir—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000978	0.00317	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000975	0.00316	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000975	0.00316	CcSEcCtD
Fosamprenavir—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000962	0.00312	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000955	0.0031	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000954	0.00309	CcSEcCtD
Fosamprenavir—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000927	0.00301	CcSEcCtD
Fosamprenavir—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000923	0.00299	CcSEcCtD
Fosamprenavir—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000923	0.00299	CcSEcCtD
Fosamprenavir—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000922	0.00299	CcSEcCtD
Fosamprenavir—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000914	0.00296	CcSEcCtD
Fosamprenavir—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000914	0.00296	CcSEcCtD
Fosamprenavir—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000911	0.00295	CcSEcCtD
Fosamprenavir—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000904	0.00293	CcSEcCtD
Fosamprenavir—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000896	0.0029	CcSEcCtD
Fosamprenavir—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000875	0.00284	CcSEcCtD
Fosamprenavir—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000872	0.00283	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000866	0.00281	CcSEcCtD
Fosamprenavir—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000863	0.0028	CcSEcCtD
Fosamprenavir—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000859	0.00279	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000858	0.00278	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000858	0.00278	CcSEcCtD
Fosamprenavir—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000847	0.00275	CcSEcCtD
Fosamprenavir—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000846	0.00274	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00084	0.00272	CcSEcCtD
Fosamprenavir—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000825	0.00268	CcSEcCtD
Fosamprenavir—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000818	0.00265	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000813	0.00264	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000813	0.00264	CcSEcCtD
Fosamprenavir—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000812	0.00263	CcSEcCtD
Fosamprenavir—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000812	0.00263	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00081	0.00263	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000796	0.00258	CcSEcCtD
Fosamprenavir—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000795	0.00258	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000788	0.00256	CcSEcCtD
Fosamprenavir—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000786	0.00255	CcSEcCtD
Fosamprenavir—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000783	0.00254	CcSEcCtD
Fosamprenavir—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00078	0.00253	CcSEcCtD
Fosamprenavir—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000779	0.00253	CcSEcCtD
Fosamprenavir—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000775	0.00251	CcSEcCtD
Fosamprenavir—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000773	0.00251	CcSEcCtD
Fosamprenavir—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000771	0.0025	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00077	0.0025	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00077	0.0025	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000767	0.00249	CcSEcCtD
Fosamprenavir—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000766	0.00248	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000754	0.00244	CcSEcCtD
Fosamprenavir—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000744	0.00241	CcSEcCtD
Fosamprenavir—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000744	0.00241	CcSEcCtD
Fosamprenavir—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000744	0.00241	CcSEcCtD
Fosamprenavir—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000744	0.00241	CcSEcCtD
Fosamprenavir—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000742	0.0024	CcSEcCtD
Fosamprenavir—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000735	0.00238	CcSEcCtD
Fosamprenavir—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000735	0.00238	CcSEcCtD
Fosamprenavir—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000735	0.00238	CcSEcCtD
Fosamprenavir—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000731	0.00237	CcSEcCtD
Fosamprenavir—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000729	0.00236	CcSEcCtD
Fosamprenavir—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000729	0.00236	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000727	0.00236	CcSEcCtD
Fosamprenavir—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000721	0.00234	CcSEcCtD
Fosamprenavir—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000718	0.00233	CcSEcCtD
Fosamprenavir—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000703	0.00228	CcSEcCtD
Fosamprenavir—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000703	0.00228	CcSEcCtD
Fosamprenavir—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000693	0.00225	CcSEcCtD
Fosamprenavir—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000693	0.00225	CcSEcCtD
Fosamprenavir—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000693	0.00225	CcSEcCtD
Fosamprenavir—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000679	0.0022	CcSEcCtD
Fosamprenavir—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000675	0.00219	CcSEcCtD
Fosamprenavir—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000675	0.00219	CcSEcCtD
Fosamprenavir—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000666	0.00216	CcSEcCtD
Fosamprenavir—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000666	0.00216	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000665	0.00216	CcSEcCtD
Fosamprenavir—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000661	0.00215	CcSEcCtD
Fosamprenavir—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000655	0.00212	CcSEcCtD
Fosamprenavir—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000652	0.00212	CcSEcCtD
Fosamprenavir—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000644	0.00209	CcSEcCtD
Fosamprenavir—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000644	0.00209	CcSEcCtD
Fosamprenavir—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000638	0.00207	CcSEcCtD
Fosamprenavir—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000631	0.00205	CcSEcCtD
Fosamprenavir—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000629	0.00204	CcSEcCtD
Fosamprenavir—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000622	0.00202	CcSEcCtD
Fosamprenavir—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000622	0.00202	CcSEcCtD
Fosamprenavir—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00061	0.00198	CcSEcCtD
Fosamprenavir—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000609	0.00198	CcSEcCtD
Fosamprenavir—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000608	0.00197	CcSEcCtD
Fosamprenavir—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000598	0.00194	CcSEcCtD
Fosamprenavir—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000598	0.00194	CcSEcCtD
Fosamprenavir—Rash—Formoterol—chronic obstructive pulmonary disease	0.000593	0.00192	CcSEcCtD
Fosamprenavir—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000593	0.00192	CcSEcCtD
Fosamprenavir—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000593	0.00192	CcSEcCtD
Fosamprenavir—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000593	0.00192	CcSEcCtD
Fosamprenavir—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00059	0.00191	CcSEcCtD
Fosamprenavir—Headache—Formoterol—chronic obstructive pulmonary disease	0.00059	0.00191	CcSEcCtD
Fosamprenavir—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000588	0.00191	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000588	0.00191	CcSEcCtD
Fosamprenavir—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000586	0.0019	CcSEcCtD
Fosamprenavir—Rash—Montelukast—chronic obstructive pulmonary disease	0.000581	0.00189	CcSEcCtD
Fosamprenavir—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000581	0.00188	CcSEcCtD
Fosamprenavir—Headache—Montelukast—chronic obstructive pulmonary disease	0.000578	0.00187	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000573	0.00186	CcSEcCtD
Fosamprenavir—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000571	0.00185	CcSEcCtD
Fosamprenavir—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000569	0.00185	CcSEcCtD
Fosamprenavir—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000565	0.00183	CcSEcCtD
Fosamprenavir—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00056	0.00182	CcSEcCtD
Fosamprenavir—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00056	0.00182	CcSEcCtD
Fosamprenavir—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000559	0.00181	CcSEcCtD
Fosamprenavir—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000559	0.00181	CcSEcCtD
Fosamprenavir—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000557	0.00181	CcSEcCtD
Fosamprenavir—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000548	0.00178	CcSEcCtD
Fosamprenavir—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000528	0.00171	CcSEcCtD
Fosamprenavir—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000524	0.0017	CcSEcCtD
Fosamprenavir—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000521	0.00169	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000512	0.00166	CcSEcCtD
Fosamprenavir—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000471	0.00153	CcSEcCtD
Fosamprenavir—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000454	0.00147	CcSEcCtD
Fosamprenavir—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000415	0.00134	CcSEcCtD
Fosamprenavir—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000386	0.00125	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000384	0.00124	CcSEcCtD
Fosamprenavir—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000376	0.00122	CcSEcCtD
Fosamprenavir—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000363	0.00118	CcSEcCtD
Fosamprenavir—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00036	0.00117	CcSEcCtD
Fosamprenavir—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000353	0.00115	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000337	0.00109	CcSEcCtD
Fosamprenavir—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000337	0.00109	CcSEcCtD
Fosamprenavir—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000322	0.00104	CcSEcCtD
Fosamprenavir—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000321	0.00104	CcSEcCtD
Fosamprenavir—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000321	0.00104	CcSEcCtD
Fosamprenavir—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000319	0.00104	CcSEcCtD
Fosamprenavir—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000319	0.00104	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000303	0.000982	CcSEcCtD
Fosamprenavir—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000303	0.000982	CcSEcCtD
Fosamprenavir—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000293	0.00095	CcSEcCtD
Fosamprenavir—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000293	0.00095	CcSEcCtD
Fosamprenavir—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000273	0.000885	CcSEcCtD
Fosamprenavir—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000266	0.000862	CcSEcCtD
Fosamprenavir—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000262	0.00085	CcSEcCtD
Fosamprenavir—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000253	0.000822	CcSEcCtD
Fosamprenavir—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000245	0.000794	CcSEcCtD
Fosamprenavir—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000236	0.000764	CcSEcCtD
Fosamprenavir—Rash—Prednisone—chronic obstructive pulmonary disease	0.000234	0.000757	CcSEcCtD
Fosamprenavir—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000233	0.000757	CcSEcCtD
Fosamprenavir—Headache—Prednisone—chronic obstructive pulmonary disease	0.000232	0.000753	CcSEcCtD
Fosamprenavir—Nausea—Prednisone—chronic obstructive pulmonary disease	0.00022	0.000714	CcSEcCtD
